EDSA
Edesa Biotech, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.33
P/S
0.00
EV/EBITDA
-4.70
DCF Value
$1.83
FCF Yield
-16.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-55.8%
ROA
-53.1%
ROIC
-59.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.2M | $-0.28 |
| Q4 2025 | $0.00 | $-2.2M | $-0.32 |
| FY 2025 | $0.00 | $-7.2M | $-1.27 |
| Q3 2025 | $0.00 | $-1.7M | $-0.25 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
-0.68
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.